(Q34541736)

2 August 2017

1 reference

title

Clinical pharmacology and therapeutic use of the new antiepileptic drugs (English)

1 reference

2 August 2017

1 reference

Perucca E

1

1 reference

2 August 2017

1 December 2001

1 reference

Fundamental and Clinical Pharmacology

2 August 2017

1 reference

2 August 2017

15

1 reference

2 August 2017

6

1 reference

2 August 2017

405-417

1 reference

Assessing risk to benefit ratio in antiepileptic drug therapy

2 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Early identification of refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

The new generation of antiepileptic drugs: advantages and disadvantages

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

The new antiepileptic drugs: pharmacological and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Antiepileptic drugs as a cause of worsening seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

The clinical pharmacokinetics of the new antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Pharmacokinetic profile of levetiracetam: toward ideal characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

The Role of Therapeutic Drug Monitoring in Improving the Cost Effectiveness of Anticonvulsant Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Is there a role for therapeutic drug monitoring of new anticonvulsants?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Clinically relevant anti-epileptic drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Levetiracetam. A review of its adjunctive use in the management of partial onset seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Oxcarbazepine: an update of its efficacy in the management of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

New antiepileptic drugs: comparison of key clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Lamictal (lamotrigine) monotherapy for typical absence seizures in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Visual field defects with vigabatrin: epidemiology and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Commission on Outcome Measurement in Epilepsy, 1994-1997: final report

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

What can we learn from clinical trials of anticonvulsant drugs in epilepsy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

The management of epilepsy in the 1990s. Acquisitions, uncertainties and priorities for future research

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Management issues for women with epilepsy: a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Difficulties in extrapolating from clinical trial data to clinical practice: the case of antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Gabapentin for the Treatment of Postherpetic Neuralgia: A Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Lamotrigine: a review of clinical studies in bipolar disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Double-Blind, Placebo-Controlled, Lamotrigine in Treatment-Resistant Generalised Epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1472-8206.2001.00055.X

Oxcarbazepine add-on for drug-resistant partial epilepsy

21 January 2018

1 reference

12 January 2024

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD002028

Identifiers

DOI

10.1046/J.1472-8206.2001.00055.X

1 reference

2 August 2017

1 reference

PubMed ID

11860529